Fractyl Health, Inc. (NASDAQ:GUTS) Given Average Rating of “Hold” by Brokerages

Fractyl Health, Inc. (NASDAQ:GUTS) has been assigned an average recommendation of “Hold” from the five research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $5.40.

Several brokerages recently commented on GUTS. Canaccord Genuity Group reiterated a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research note on Friday, December 19th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Tuesday, December 2nd. Morgan Stanley downgraded Fractyl Health from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $8.00 to $2.00 in a research report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th.

Fractyl Health Stock Performance

Shares of GUTS opened at $0.43 on Thursday. The stock has a market capitalization of $58.31 million, a PE ratio of -0.19 and a beta of 1.64. Fractyl Health has a 1 year low of $0.41 and a 1 year high of $3.03. The company’s 50-day simple moving average is $1.92 and its 200-day simple moving average is $1.49.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). On average, sell-side analysts predict that Fractyl Health will post -1.61 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd acquired a new stake in Fractyl Health in the second quarter worth $181,000. UBS Group AG raised its stake in Fractyl Health by 48.0% during the 4th quarter. UBS Group AG now owns 1,113,982 shares of the company’s stock valued at $2,451,000 after acquiring an additional 361,386 shares in the last quarter. FNY Investment Advisers LLC grew its stake in shares of Fractyl Health by 143.3% in the fourth quarter. FNY Investment Advisers LLC now owns 48,650 shares of the company’s stock worth $107,000 after purchasing an additional 28,650 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in Fractyl Health during the 3rd quarter valued at about $81,000. Finally, Scientech Research LLC bought a new stake in Fractyl Health during the third quarter worth approximately $49,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.